- Email: [email protected]
4783401 Viable cell labelling
96
PATENT ABSTRACTS
4782018 DETECTION OF HYDROLYZING ENZYMES Jon Eikenberry, Karen L Warren, Brooke Schlegel, Dolores Humbert assigned to Eastman Kodak Company A composition of a polysaccharide with a detectable material appended thereto and a 1,3-dione having a methylene group between the two carbonyls of the 1,3-dione, which methylene group has at least one ionizable hydrogen, provides accurate results in assays of hydrolyzing enzymes such as amylase. The composition can be incorporated in the reagent zone of a dry test element having a reagent zone and a registration zone.
4782020 PROCESS FOR THE CONTINUOUS ENZYMATIC CONVERSION OF ALPHAHYDROCARBOXYLIC ACIDS INTO THE CORRESPONDING OPTICALLY ACTIVE ALPHAAMINOCARBOXYLIC ACIDS
4782026 COLLECTION MEDIUM WHOLE BLOOD
FOR
Robert F Baugh, Cynthia A Taylor assigned to Hemotec Inc An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.
4783400
Wolfgang Leuchtenberger, Christian Wandrey, Maria-Regina Kula, Bruchk Federal Republic Of Germana assigned to Degussa Aktiengesellschaft
HOMOGENEOUS ENZYME IMMUNOASSAY SYSTEM AND METHOD
alpha-Hydroxycarboxylic acids are continuously converted into the corresponding optically active alpha- aminocarboxylic acids. The conversion is carried out in a membrane reactor in the presence of nicotinamide-adenine dinucleotide increased in molecular weight by bonding to a water soluble high molecular weight material, a dehydrogenase specific for the alpha-hydroxycarboxylic acid, a dehydrogenase specific for the corresponding alpha-aminocarboxylic acid and ammonium ions. There is continuously supplied to the membrane reactor an aqueous solution of the alphahydroxycarboxylic acid to be reacted, a substantially lesser amount of the corresponding alphaketocarboxy lic acid, and an amount of ammonium ion at least equivalent to the alphahydroxycarboxylic acid to be reacted. There is maintained over the membrane a difference in pressure 1 and 15 bar. Behind the membrane, there is continuously drawn off a filtrate stream containing the alpha-aminocarboxylic acid formed.
Eleanor Canova-Davis, Viola T Kung, Carl T Redemann assigned to Cooper Lipotech A liposome assay reagent for determination of an analyte in a homogeneous immunoassay. The reagent includes a suspension of oligolamellar lipid vesicles containing encapsulated glucose-6phosphate dehydrogenase (G6PD), at a specific activity of between about 1-15 units/ mumole vesicle lipid, and glucose-6-phosphate (G6P) at a concentration of at least about 5 mM. The encapsulated G6P protects the enzyme against inactivation on preparation, by reverse phase evaporation in the presence of organic solvent, and on storage as an aqueous suspension.
4783401 VIABLE CELL LABELLING Paul K Horan, Bruce D Jensen, Sue Slezak assigned to SmithKline Beckman Corporation
PATENT ABSTRACTS Methods for reproducibly labelling viable cells with cyanine dyes that do not significantly affect cell viability. Applications for labelled cells include using labelled red blood cells to distinguish post-transfusional bleeding from immunologic reaction and using dilution to measure growth rate of cultured cells.
~8M19 EXAMINING CELI~ BY ELECTROPHORESIS Haruhis Hayashi, Yoshihar Oguchi, Kenich Matsunaga, Chikao Yoshikumi, Tokyo, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha Disclosed herein is a method for examining cells, comprising subjecting the cells to an antigenantibody reaction treatment, then measuring a pattern of the electrophoretic mobility of the cells and comparing the electrophoretic property of the cells under examination with the electrophoretic property of standard cells.
97
4783525 PREPARATION OF REAGENT FOR IMMUNE COMPLEX ISOLATION Thomas L McDonald assigned to The Board of Regents of the University of Nebraska To diagnose diseases in patients, a protein complex, RhC, is prepared from horse serum by precipitating a white powder from the serum at a pH of 5.5 and processing to remove lipids at a pH of 8.2 using Tris-HCl as the buffer. It includes two components associated together to provide a molecular weight of 280,000 and having characteristics of a rheumatoid factor and a Clq-like subcomponent of the complement. The protein complex is incubated with human serum or plasma and then precipitated by dialysis against a high pH buffer (0.05 M Tris-HCl pH 8.2). When precipitated, it co-precipitates the immune complexes from the human blood serum without substantial monomeric immunoglobulin to quantitatively isolate immunecomplexes from serum. Immunological assays then determine how much immune complex and what kind were in the serum.
PATENT ABSTRACTS
4782018 DETECTION OF HYDROLYZING ENZYMES Jon Eikenberry, Karen L Warren, Brooke Schlegel, Dolores Humbert assigned to Eastman Kodak Company A composition of a polysaccharide with a detectable material appended thereto and a 1,3-dione having a methylene group between the two carbonyls of the 1,3-dione, which methylene group has at least one ionizable hydrogen, provides accurate results in assays of hydrolyzing enzymes such as amylase. The composition can be incorporated in the reagent zone of a dry test element having a reagent zone and a registration zone.
4782020 PROCESS FOR THE CONTINUOUS ENZYMATIC CONVERSION OF ALPHAHYDROCARBOXYLIC ACIDS INTO THE CORRESPONDING OPTICALLY ACTIVE ALPHAAMINOCARBOXYLIC ACIDS
4782026 COLLECTION MEDIUM WHOLE BLOOD
FOR
Robert F Baugh, Cynthia A Taylor assigned to Hemotec Inc An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.
4783400
Wolfgang Leuchtenberger, Christian Wandrey, Maria-Regina Kula, Bruchk Federal Republic Of Germana assigned to Degussa Aktiengesellschaft
HOMOGENEOUS ENZYME IMMUNOASSAY SYSTEM AND METHOD
alpha-Hydroxycarboxylic acids are continuously converted into the corresponding optically active alpha- aminocarboxylic acids. The conversion is carried out in a membrane reactor in the presence of nicotinamide-adenine dinucleotide increased in molecular weight by bonding to a water soluble high molecular weight material, a dehydrogenase specific for the alpha-hydroxycarboxylic acid, a dehydrogenase specific for the corresponding alpha-aminocarboxylic acid and ammonium ions. There is continuously supplied to the membrane reactor an aqueous solution of the alphahydroxycarboxylic acid to be reacted, a substantially lesser amount of the corresponding alphaketocarboxy lic acid, and an amount of ammonium ion at least equivalent to the alphahydroxycarboxylic acid to be reacted. There is maintained over the membrane a difference in pressure 1 and 15 bar. Behind the membrane, there is continuously drawn off a filtrate stream containing the alpha-aminocarboxylic acid formed.
Eleanor Canova-Davis, Viola T Kung, Carl T Redemann assigned to Cooper Lipotech A liposome assay reagent for determination of an analyte in a homogeneous immunoassay. The reagent includes a suspension of oligolamellar lipid vesicles containing encapsulated glucose-6phosphate dehydrogenase (G6PD), at a specific activity of between about 1-15 units/ mumole vesicle lipid, and glucose-6-phosphate (G6P) at a concentration of at least about 5 mM. The encapsulated G6P protects the enzyme against inactivation on preparation, by reverse phase evaporation in the presence of organic solvent, and on storage as an aqueous suspension.
4783401 VIABLE CELL LABELLING Paul K Horan, Bruce D Jensen, Sue Slezak assigned to SmithKline Beckman Corporation
PATENT ABSTRACTS Methods for reproducibly labelling viable cells with cyanine dyes that do not significantly affect cell viability. Applications for labelled cells include using labelled red blood cells to distinguish post-transfusional bleeding from immunologic reaction and using dilution to measure growth rate of cultured cells.
~8M19 EXAMINING CELI~ BY ELECTROPHORESIS Haruhis Hayashi, Yoshihar Oguchi, Kenich Matsunaga, Chikao Yoshikumi, Tokyo, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha Disclosed herein is a method for examining cells, comprising subjecting the cells to an antigenantibody reaction treatment, then measuring a pattern of the electrophoretic mobility of the cells and comparing the electrophoretic property of the cells under examination with the electrophoretic property of standard cells.
97
4783525 PREPARATION OF REAGENT FOR IMMUNE COMPLEX ISOLATION Thomas L McDonald assigned to The Board of Regents of the University of Nebraska To diagnose diseases in patients, a protein complex, RhC, is prepared from horse serum by precipitating a white powder from the serum at a pH of 5.5 and processing to remove lipids at a pH of 8.2 using Tris-HCl as the buffer. It includes two components associated together to provide a molecular weight of 280,000 and having characteristics of a rheumatoid factor and a Clq-like subcomponent of the complement. The protein complex is incubated with human serum or plasma and then precipitated by dialysis against a high pH buffer (0.05 M Tris-HCl pH 8.2). When precipitated, it co-precipitates the immune complexes from the human blood serum without substantial monomeric immunoglobulin to quantitatively isolate immunecomplexes from serum. Immunological assays then determine how much immune complex and what kind were in the serum.